In this week's Peer Review: Juan Andres returns to Moderna as COO, Eiry Roberts is back as Neurocrine's CMO, and Pharming CEO Fabrice Chouraqui exits.
endpoints.news/moderna-neur...
endpoints.news/moderna-neur...
Moderna, Neurocrine bring back familiar faces; Pharming CEO exits after clashing with board
Juan Andres will come out of retirement to rejoin Moderna as COO on Oct. 5, bringing his intimate knowledge of the company as its Merck-partnered cancer vaccine gathers momentum in the clinic.
endpoints.news
October 2, 2026 at 2:05 PM
In this week's Peer Review: Juan Andres returns to Moderna as COO, Eiry Roberts is back as Neurocrine's CMO, and Pharming CEO Fabrice Chouraqui exits.
endpoints.news/moderna-neur...
endpoints.news/moderna-neur...
Neurocrine Biosciences Showcases PWS Research and VYKAT XR at 2026 Conference#USA#Philadelphia#Neurocrine#VYKAT_XR#Prader-Willi_Syndrome
Neurocrine Biosciences Showcases PWS Research and VYKAT XR at 2026 Conference
Neurocrine Biosciences presents crucial research at the Foundation for Prader-Willi Research Symposium focusing on VYKAT XR for Prader-Willi Syndrome.
third-news.com
September 30, 2026 at 12:44 PM
Neurocrine Biosciences Showcases PWS Research and VYKAT XR at 2026 Conference#USA#Philadelphia#Neurocrine#VYKAT_XR#Prader-Willi_Syndrome
Ruder Finn Wins Neurocrine Biosciences US AOR
Ruder Finn Wins Neurocrine Biosciences US AOR
The agency will handle product and pipeline communications, corporate reputation, digital and creative work.
www.provokemedia.com
September 29, 2026 at 2:16 PM
Ruder Finn Wins Neurocrine Biosciences US AOR
The groups did not tell anyone to stop. They asked for careful patient selection and closer monitoring. Neurocrine says it stands behind the safety profile, and the FDA hadn't issued a communication or label change as of mid-August. (Not medical advice.)
September 29, 2026 at 1:00 PM
The groups did not tell anyone to stop. They asked for careful patient selection and closer monitoring. Neurocrine says it stands behind the safety profile, and the FDA hadn't issued a communication or label change as of mid-August. (Not medical advice.)
NEUROCRINE BIOSCIENCES INC (0000914475) (Filer) (cik: 0000914475) filed an 8-K update with an Item 5.02. See the filing at https://www.sec.gov/Archives/edgar/data/914475/000091447526000045/0000914475-26-000045-index.htm
September 28, 2026 at 8:41 PM
NEUROCRINE BIOSCIENCES INC (0000914475) (Filer) (cik: 0000914475) filed an 8-K update with an Item 5.02. See the filing at https://www.sec.gov/Archives/edgar/data/914475/000091447526000045/0000914475-26-000045-index.htm
🚨 $NBIX
On September 28, 2026, the Board of Directors of Neurocrine Biosciences, Inc. appointed Eiry W. Roberts, M.D., to succeed Sanjay Keswani, M.D., as the Company’s Chief Medical Officer, effective September 28, 2026 . On September 25, 2026, Dr. Keswani and the Board mutually agreed that Dr. ...
On September 28, 2026, the Board of Directors of Neurocrine Biosciences, Inc. appointed Eiry W. Roberts, M.D., to succeed Sanjay Keswani, M.D., as the Company’s Chief Medical Officer, effective September 28, 2026 . On September 25, 2026, Dr. Keswani and the Board mutually agreed that Dr. ...
SEC Filing: NBIX
Click to view the official SEC document.
www.sec.gov
September 28, 2026 at 8:26 PM
🚨 $NBIX
On September 28, 2026, the Board of Directors of Neurocrine Biosciences, Inc. appointed Eiry W. Roberts, M.D., to succeed Sanjay Keswani, M.D., as the Company’s Chief Medical Officer, effective September 28, 2026 . On September 25, 2026, Dr. Keswani and the Board mutually agreed that Dr. ...
On September 28, 2026, the Board of Directors of Neurocrine Biosciences, Inc. appointed Eiry W. Roberts, M.D., to succeed Sanjay Keswani, M.D., as the Company’s Chief Medical Officer, effective September 28, 2026 . On September 25, 2026, Dr. Keswani and the Board mutually agreed that Dr. ...
Neurocrine Biosciences Welcomes Dr. Eiry W. Roberts Back as Chief Medical Officer#United_States#San_Diego#Neurocrine_Biosciences#INGREZZA#Eiry_W._Roberts
Neurocrine Biosciences Welcomes Dr. Eiry W. Roberts Back as Chief Medical Officer
Neurocrine Biosciences has appointed Dr. Eiry W. Roberts as Chief Medical Officer again, bringing her extensive experience back to the team. This move comes as the company prepares for important clinical milestones.
third-news.com
September 28, 2026 at 8:16 PM
Neurocrine Biosciences Welcomes Dr. Eiry W. Roberts Back as Chief Medical Officer#United_States#San_Diego#Neurocrine_Biosciences#INGREZZA#Eiry_W._Roberts
Thanks to our RISW supporting sponsors: Argenx; Astellas; BlankBio; CIMS; Clindata; DuBu Research; HopeAI; Innovatio Statistics; Neurocrine Biosciences; NouStarX; Otsuka; Penfield; Phase V; Phastar; Quantive Intelligence; Regeneron; Servier; Stata; The Lotus Group; VeraMed; & Vertex.
September 18, 2026 at 10:18 PM
Thanks to our RISW supporting sponsors: Argenx; Astellas; BlankBio; CIMS; Clindata; DuBu Research; HopeAI; Innovatio Statistics; Neurocrine Biosciences; NouStarX; Otsuka; Penfield; Phase V; Phastar; Quantive Intelligence; Regeneron; Servier; Stata; The Lotus Group; VeraMed; & Vertex.
Verkkotunnus: ampavance.fi
Rekisteröity: 2026-09-18 17:06
Käyttäjä: Neurocrine Switzerland GmbH
Maa: Sveitsi
Välittäjä: Key-Systems GmbH
Rekisteröity: 2026-09-18 17:06
Käyttäjä: Neurocrine Switzerland GmbH
Maa: Sveitsi
Välittäjä: Key-Systems GmbH
September 18, 2026 at 10:11 PM
Verkkotunnus: ampavance.fi
Rekisteröity: 2026-09-18 17:06
Käyttäjä: Neurocrine Switzerland GmbH
Maa: Sveitsi
Välittäjä: Key-Systems GmbH
Rekisteröity: 2026-09-18 17:06
Käyttäjä: Neurocrine Switzerland GmbH
Maa: Sveitsi
Välittäjä: Key-Systems GmbH
Thanks to our #RISW2026 supporting sponsors: Argenx; Astellas; BlankBio; CIMS; Clindata; DuBu Research; HopeAI; Innovatio Statistics; Neurocrine Biosciences; NouStarX; Otsuka; Penfield; Phase V; Phastar; Quantive Intelligence; Regeneron; Servier; Stata; The Lotus Group; VeraMed; & Vertex. #STATSSKY
September 17, 2026 at 7:57 PM
Thank you Neurocrine Biosciences for your NNDC Annual Conference Silver Sponsorship!
NNDC 2026 Annual Conference
October 19-20, 2026 | The Texas Union | 2247 Guadalupe St, Austin, Texas
More Information: nndc.org/nndc-annual-...
NNDC 2026 Annual Conference
October 19-20, 2026 | The Texas Union | 2247 Guadalupe St, Austin, Texas
More Information: nndc.org/nndc-annual-...
September 17, 2026 at 5:31 PM
Thank you Neurocrine Biosciences for your NNDC Annual Conference Silver Sponsorship!
NNDC 2026 Annual Conference
October 19-20, 2026 | The Texas Union | 2247 Guadalupe St, Austin, Texas
More Information: nndc.org/nndc-annual-...
NNDC 2026 Annual Conference
October 19-20, 2026 | The Texas Union | 2247 Guadalupe St, Austin, Texas
More Information: nndc.org/nndc-annual-...
Thanks to our RISW supporting sponsors: Argenx; Astellas; BlankBio; CIMS; Clindata; DuBu Research; HopeAI; Innovatio Statistics; Neurocrine Biosciences; NouStarX; Otsuka; Penfield; Phase V; Phastar; Quantive Intelligence; Regeneron; Servier; Stata; The Lotus Group; VeraMed; & Vertex.
September 16, 2026 at 4:50 PM
Thanks to our RISW supporting sponsors: Argenx; Astellas; BlankBio; CIMS; Clindata; DuBu Research; HopeAI; Innovatio Statistics; Neurocrine Biosciences; NouStarX; Otsuka; Penfield; Phase V; Phastar; Quantive Intelligence; Regeneron; Servier; Stata; The Lotus Group; VeraMed; & Vertex.
📄 #NBIX 10-Q — what changed
MD&A now says: "Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in Part II, Item 1A under the caption "Risk Factors." The interim financial statements and this
MD&A now says: "Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in Part II, Item 1A under the caption "Risk Factors." The interim financial statements and this
FormDelta — Insider Trading Alerts
What NEUROCRINE BIOSCIENCES INC changed in their own words, quarter over quarter.
www.formdelta.com
September 11, 2026 at 12:33 AM
📄 #NBIX 10-Q — what changed
MD&A now says: "Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in Part II, Item 1A under the caption "Risk Factors." The interim financial statements and this
MD&A now says: "Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in Part II, Item 1A under the caption "Risk Factors." The interim financial statements and this
Join the #HDSA Utah Chapter for Education Day!
Learn about caregiver resources, disability and legal planning, HD research and more.
📅 Oct. 17, 2026
⏰ Check-in: 9:30 a.m.
📍 Imaging & Neurosciences Center
Register: utah.hdsa.org/edday
#HuntingtonsDisease
Learn about caregiver resources, disability and legal planning, HD research and more.
📅 Oct. 17, 2026
⏰ Check-in: 9:30 a.m.
📍 Imaging & Neurosciences Center
Register: utah.hdsa.org/edday
#HuntingtonsDisease
September 10, 2026 at 11:10 PM
Join the #HDSA Utah Chapter for Education Day!
Learn about caregiver resources, disability and legal planning, HD research and more.
📅 Oct. 17, 2026
⏰ Check-in: 9:30 a.m.
📍 Imaging & Neurosciences Center
Register: utah.hdsa.org/edday
#HuntingtonsDisease
Learn about caregiver resources, disability and legal planning, HD research and more.
📅 Oct. 17, 2026
⏰ Check-in: 9:30 a.m.
📍 Imaging & Neurosciences Center
Register: utah.hdsa.org/edday
#HuntingtonsDisease
Neurocrine Biosciences to Showcase Innovations at Upcoming Investor Conferences#United_States#San_Diego#biopharmaceuticals#Investor_Conferences#Neurocrine_Biosciences
Neurocrine Biosciences to Showcase Innovations at Upcoming Investor Conferences
Neurocrine Biosciences is set to present at key investor conferences in September 2026, discussing their innovative treatments and pipeline.
third-news.com
September 2, 2026 at 8:14 PM
Neurocrine Biosciences to Showcase Innovations at Upcoming Investor Conferences#United_States#San_Diego#biopharmaceuticals#Investor_Conferences#Neurocrine_Biosciences
📢 Atlantic) is #hiring a Assoc. Field Medical Marketing Director (mid!
🌎 Neurocrine Biosciences
🔗 http://jbs.ink/edhNPniHFY2B
#jobalert #jobsearch #ecommercejobs #marketing
🌎 Neurocrine Biosciences
🔗 http://jbs.ink/edhNPniHFY2B
#jobalert #jobsearch #ecommercejobs #marketing
September 1, 2026 at 8:16 PM
📢 Atlantic) is #hiring a Assoc. Field Medical Marketing Director (mid!
🌎 Neurocrine Biosciences
🔗 http://jbs.ink/edhNPniHFY2B
#jobalert #jobsearch #ecommercejobs #marketing
🌎 Neurocrine Biosciences
🔗 http://jbs.ink/edhNPniHFY2B
#jobalert #jobsearch #ecommercejobs #marketing
📢 Neurocrine Biosciences is #hiring a Sr. Director, Epidemiology & Rwe Analytics!
🌎 San Diego, California, United States
🔗 http://jbs.ink/ToNW7cXtJkAC
#jobalert #jobsearch #familyofficejobs #marketing #design
🌎 San Diego, California, United States
🔗 http://jbs.ink/ToNW7cXtJkAC
#jobalert #jobsearch #familyofficejobs #marketing #design
August 28, 2026 at 3:59 PM
📢 Neurocrine Biosciences is #hiring a Sr. Director, Epidemiology & Rwe Analytics!
🌎 San Diego, California, United States
🔗 http://jbs.ink/ToNW7cXtJkAC
#jobalert #jobsearch #familyofficejobs #marketing #design
🌎 San Diego, California, United States
🔗 http://jbs.ink/ToNW7cXtJkAC
#jobalert #jobsearch #familyofficejobs #marketing #design
#NeurocrineBiosciences - partnered with Japan’s #NxeraPharma - has announced it has received IND Acceptance from the #FDA for a Phase 2 study of NBI-1117567 (“NBI-’567”) for #Alzheimers cognition.
pharmaphorum.com/news/neurocr...
pharmaphorum.com/news/neurocr...
Neurocrine receives FDA IND Acceptance for Alzheimer’s Ph2
Nxera Pharma has announced that partner Neurocrine Biosciences has received IND Acceptance from the FDA a Ph2 of NBI-1117567 in Alzheimer's cognition.
pharmaphorum.com
August 26, 2026 at 10:10 AM
#NeurocrineBiosciences - partnered with Japan’s #NxeraPharma - has announced it has received IND Acceptance from the #FDA for a Phase 2 study of NBI-1117567 (“NBI-’567”) for #Alzheimers cognition.
pharmaphorum.com/news/neurocr...
pharmaphorum.com/news/neurocr...
The groups did not tell anyone to stop. They asked for careful patient selection and closer monitoring. Neurocrine says it stands behind the safety profile, and the FDA hadn't issued a communication or label change as of mid-August. (Not medical advice.)
August 25, 2026 at 6:27 PM
The groups did not tell anyone to stop. They asked for careful patient selection and closer monitoring. Neurocrine says it stands behind the safety profile, and the FDA hadn't issued a communication or label change as of mid-August. (Not medical advice.)